Your browser doesn't support javascript.
loading
Seroprevalence of SARS-CoV-2 antibodies, associated epidemiological factors and antibody kinetics among healthcare workers in Connecticut.
Papasavas, P; Olugbile, S; Wu, U; Robinson, K; Roberts, A L; O'Sullivan, D M; McLaughlin, T; Mather, J F; Steinberg, A C; Orlando, R; Kumar, A.
Affiliation
  • Papasavas P; Department of Surgery, Hartford Hospital, Hartford, CT, USA. Electronic address: pavlos.papasavas@hhchealth.org.
  • Olugbile S; Cancer Institute, Hartford HealthCare, Hartford, CT, USA.
  • Wu U; Administration, Hartford HealthCare, Hartford, CT, USA.
  • Robinson K; Department of Emergency Medicine, Hartford Hospital, Hartford, CT, USA.
  • Roberts AL; Department of Clinical Laboratory Services: Microbiology, Hartford HealthCare, Hartford, CT, USA.
  • O'Sullivan DM; Hartford Healthcare Research Program, Hartford, CT, USA.
  • McLaughlin T; Department of Surgery, Hartford Hospital, Hartford, CT, USA.
  • Mather JF; Hartford Healthcare Research Program, Hartford, CT, USA.
  • Steinberg AC; Department of Medical Affairs, Hartford HealthCare, Hartford, CT, USA.
  • Orlando R; Department of Academic Affairs, Hartford HealthCare, Hartford, CT, USA.
  • Kumar A; Clinical Affairs, Hartford HealthCare, Hartford, CT, USA.
J Hosp Infect ; 114: 117-125, 2021 Aug.
Article in En | MEDLINE | ID: mdl-33930487
ABSTRACT

BACKGROUND:

Healthcare workers (HCWs) are at the front line of the ongoing coronavirus 2019 (COVID-19) pandemic. Comprehensive evaluation of the seroprevalence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) among HCWs in a large healthcare system could help to identify the impact of epidemiological factors and the presence of symptoms on the immune response to the infection over time.

AIM:

To determine the seroprevalence of SARS-CoV-2-specific antibodies among HCWs, identify associated epidemiological factors and study antibody kinetics.

METHODS:

A longitudinal evaluation of the seroprevalence and epidemiology of SARS-CoV-2-specific antibodies was undertaken in approximately 30,000 HCWs in the largest healthcare system in Connecticut, USA.

FINDINGS:

At baseline, the prevalence of SARS-CoV-2 antibody among 6863 HCWs was 6.3% [95% confidence interval (CI) 5.7-6.9%], and was highest among patient care support (16.7%), medical assistants (9.1%) and nurses (8.2%), and lower for physicians (3.8%) and advanced practice providers (4.5%). Seroprevalence was significantly higher among African Americans [odds ratio (OR) 3.26 compared with Caucasians, 95% CI 1.77-5.99], in participants with at least one symptom of COVID-19 (OR 3.00, 95% CI 1.92-4.68), and in those reporting prior quarantine (OR 3.83, 95% CI 2.57-5.70). No symptoms were reported in 24% of seropositive participants. Among the 47% of participants who returned for a follow-up serological test, the seroreversion rate was 39.5% and the seroconversion rate was 2.2%. The incidence of re-infection in the seropositive group was zero.

CONCLUSION:

Although there is a decline in the immunoglobulin G antibody signal over time, 60.5% of seropositive HCWs had maintained their seroconversion status after a median of 5.5 months.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 / Antibodies, Viral Type of study: Prognostic_studies / Risk_factors_studies Limits: Adult / Female / Humans / Male / Middle aged Country/Region as subject: America do norte Language: En Journal: J Hosp Infect Year: 2021 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 / Antibodies, Viral Type of study: Prognostic_studies / Risk_factors_studies Limits: Adult / Female / Humans / Male / Middle aged Country/Region as subject: America do norte Language: En Journal: J Hosp Infect Year: 2021 Document type: Article